Crystalline T-type calcium channel salt patent
Summary
The USPTO published patent application US20260092036A1 by inventors Daniel Thomas Walters and Thomas San Ie on April 2, 2026. The application discloses Pattern D, a crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1), along with pharmaceutical compositions and methods for treating neurological and psychiatric disorders. The application was originally filed on August 27, 2025, with application number 19311030.
What changed
The USPTO published patent application US20260092036A1 for a crystalline salt of a T-type calcium channel modulator designated Pattern D. The invention comprises Compound 1, a hydrochloride salt trihydrate of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide, along with pharmaceutical compositions and methods of treating neurological and psychiatric disorders using the crystalline form.
This publication represents the standard 18-month pre-grant publication of the patent application and does not require any immediate action from pharmaceutical companies or researchers. Entities developing T-type calcium channel modulators or working in neurological/psychiatric disorder therapeutics should review the claimed crystalline form and its specifications to assess potential freedom-to-operate considerations or prior art implications for their own R&D programs.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CRYSTALLINE SALTS OF A T-TYPE CALCIUM CHANNEL MODULATOR AND METHODS OF USE THEREOF
Application US20260092036A1 Kind: A1 Apr 02, 2026
Inventors
Daniel Thomas Walters, Thomas San Ie
Abstract
The present disclosure provides Pattern D, i.e., a crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1). The present disclosure also provides pharmaceutical compositions comprising Compound 1 in the form of Pattern D, as well as methods of treating neurological and psychiatric disorders by administering to a subject in need thereof Compound 1 in the form of Pattern D or a pharmaceutical composition comprising Compound 1 in the form of Pattern D.
CPC Classifications
C07D 211/26 A61K 31/445 A61K 47/38
Filing Date
2025-08-27
Application No.
19311030
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.